Personalized Diagnostics

Personalized Diagnostics

By Joseph Anderson, MDNewsScienceMedicineHealth & FitnessTech NewsLife Sciences
Download on the App Store

Personalized Diagnostics episodes

  • TRACY GEORGE, MD - EXECUTIVE DIRECTOR OF CLINICAL TRIALS AND PHARMADX AT ARUP LABORATORIES - PREVIEW 3
    With the advent of next generation sequencing, we've gained the ability to test for nearly any and all genomic alterations – many or most of which are benign or of uncertain significance.
    And, believe it or not, we encounter many benign or uncertain alterations in tumor related genes.
    Targeted therapies have historically been developed with a relatively small number of alterations in mind. For example, KRAS testing focused originally only on codon 12 and 13 mutations. While, 90% of deleterious EGFR alterations in lung #cancer are either chromosome 19 deletion or the L858R mutation.
    Are we in danger of watering down the size of the effect in clinical trials for targeted therapies by trying to incorporate too many genomic alterations in their #design?
    1 min
  • TRACY GEORGE, MD - EXECUTIVE DIRECTOR OF CLINICAL TRIALS AND PHARMADX AT ARUP LABORATORIES - Preview 1
    September 25, 1998 - trastuzumab, one of the first targeted therapies with a companion diagnostic, received #FDA approval in breast #cancer.
    The commercially available IHC and FISH companion #diagnostics were not incorporated into the pivotal clinical trial. They had to be subsequently "developed" and validated by way of concordance studies (which were not stellar).
    Does this still happen today? Have we begun to appreciate the importance of embedding companion diagnostics directly into clinical trials?
    1 min
  • Tracy George, MD - Executive Director of clinical trials and pharmaDX at ARUP Laboratories - Episode 17
    Over the past 20 years we've seen the development of approximately 40 indications for targeted therapies with a companion diagnostic. How can we continue to build on these successes and develop even more effective strategies for developing targeted therapies with companion diagnostics and incorporating diagnostics into clinical trials?
    Our guest is Tracy George, MD, Professor of Pathology at the University of Utah and the Executive Director of clinical trials and pharma DX at ARUP Laboratories.
    26 min
  • DR. TOM STUBBS, CO-FOUNDER AND CEO OF CHRONOMICS - PREVIEW 3
    We’ve all heard the term “epigenetics.” But what does it actually mean?
    #Epigenetics is the study of changes in organisms caused by modification of gene expression rather than alteration of the genetic code itself.
    It is somewhat of a catch-all term and does not apply to any one type of change or any one methodology for measuring these changes.
    1 min
  • Hagenkord's Korner - Preview 2
    Slow down - testing for SARS-CoV-2 is not as simple as it may seem.
    “What I really want to know is: if this test result is positive, what are the chances that my patient actually has the condition.
    “Sensitivity and specificity really have no utility in a practical everyday clinical setting.
    “You really want to know the positive predictive value and the negative predictive value.”
    4 min
  • Hagenkord's Korner - preview 1
    Slow down - testing for SARS-CoV-2 is complicated.
    Jill Hagenkord, MD, FCAP is co-founder and CMO of MDisrupt, as well as previously serving as CMO at Invitae, Complete Genomics Inc., Color, and 23andMe.
    She joins us for this first installment of "Hagenkord's Korner."
    3 min

About Personalized Diagnostics

From the publisher's feed

Welcome to the Personalized Diagnostics Podcast.